CD34 and neoplasm: The therapeutic potential and activity of LY3300054 in the context of more completely human immune-replete animals was assessed in immunodeficient NSG or NOG mice engrafted with HSCs of human origin (CD34+ huHSCs), and two xenograft mouse tumor models, using the HCC827 and OV79 tumor cell lines.